Rhodium complex RhLI2I: a novel anticancer agent inducing tumor inhibition and apoptosis

Rhodium complex RhLI2I: a novel anticancer agent inducing tumor inhibition and apoptosis

Numerous chemotherapeutic agents are currently employed in cancer treatment, but many are associated with significant side effects. This study aims to identify a novel anticancer drug that minimizes or eliminates these adverse effects. The anticancer activity of the Rhodium (III) complex cis-[RhLI2]...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Discover. Oncology 2024-12, Vol.15 (1), p.782
Hauptverfasser: Hossain, M Matakabbir, Soha, Kazi, Rahman, Arifur, Auwal, Abdul, Pronoy, Tasfik Ul Haque, Rashel, K M, Nurujjaman, M, Rahman, Habibur, Roy, Tapashi G, Khanam, Jahan Ara, Islam, Farhadul
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 782
container_title Discover. Oncology
container_volume 15
creator Hossain, M Matakabbir
Soha, Kazi
Rahman, Arifur
Auwal, Abdul
Pronoy, Tasfik Ul Haque
Rashel, K M
Nurujjaman, M
Rahman, Habibur
Roy, Tapashi G
Khanam, Jahan Ara
Islam, Farhadul
description Numerous chemotherapeutic agents are currently employed in cancer treatment, but many are associated with significant side effects. This study aims to identify a novel anticancer drug that minimizes or eliminates these adverse effects. The anticancer activity of the Rhodium (III) complex cis-[RhLI2]I was evaluated through both in vivo and in vitro functional assays. Apoptosis in cancer cells post-treatment was assessed using microscopy and gene expression analysis. In cytotoxicity screening via the brine shrimp lethality bioassay, the compound exhibited an LC50 value of 25.90 µg/mL (P 
doi_str_mv 10.1007/s12672-024-01632-7
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146953647</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146953647</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_31469536473</originalsourceid><addsrcrecordid>eNqVirFKBDEUAIMoeOj9gNUrbaIvyW6CtqJ4YHVcYXfEbLyNZPPWfYn4-V5hYWs1MzBCXCm8UYjulpW2TkvUnURljZbuRKy0MygtKnX6x8_FmvkDEXWvjMF-JV63Iw2pTRBomnP8hu34stGbe_BQ6Ctm8KWm4EuIC_hDLBVSGVpI5QC1TbQcc0xvqSYqx3UAP9NciRNfirN3nzmuf3khrp8edw_Pcl7os0Wu-ylxiDn7Eqnx3qjO3vXGds78Y_0BBSBNIA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146953647</pqid></control><display><type>article</type><title>Rhodium complex RhLI2I: a novel anticancer agent inducing tumor inhibition and apoptosis</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><creator>Hossain, M Matakabbir ; Soha, Kazi ; Rahman, Arifur ; Auwal, Abdul ; Pronoy, Tasfik Ul Haque ; Rashel, K M ; Nurujjaman, M ; Rahman, Habibur ; Roy, Tapashi G ; Khanam, Jahan Ara ; Islam, Farhadul</creator><creatorcontrib>Hossain, M Matakabbir ; Soha, Kazi ; Rahman, Arifur ; Auwal, Abdul ; Pronoy, Tasfik Ul Haque ; Rashel, K M ; Nurujjaman, M ; Rahman, Habibur ; Roy, Tapashi G ; Khanam, Jahan Ara ; Islam, Farhadul</creatorcontrib><description><![CDATA[Numerous chemotherapeutic agents are currently employed in cancer treatment, but many are associated with significant side effects. This study aims to identify a novel anticancer drug that minimizes or eliminates these adverse effects. The anticancer activity of the Rhodium (III) complex cis-[RhLI2]I was evaluated through both in vivo and in vitro functional assays. Apoptosis in cancer cells post-treatment was assessed using microscopy and gene expression analysis. In cytotoxicity screening via the brine shrimp lethality bioassay, the compound exhibited an LC50 value of 25.90 µg/mL (P < 0.001). It also achieved an 88.96% inhibition of cell growth (P < 0.001), an 82.39% increase in lifespan (P < 0.001), and a significant reduction in tumor weight at a dosage of 200 µg/kg in Ehrlich ascites carcinoma (EAC)-bearing Swiss albino mice. Restoration of hematological parameters, such as RBC, WBC, and hemoglobin levels, was observed in treated tumor-bearing mice compared to untreated EAC-bearing mice. The compound inhibited the growth and proliferation of breast cancer (MCF7) cells in a dose-dependent manner, achieving a maximum inhibition of 88.9% at 200 µg/mL. Apoptotic induction in MCF7 cells occurred through the upregulation of p53, Bax, caspase-3, -8, and -9, alongside the downregulation of the anti-apoptotic protein Bcl-2. No long-term adverse effects on hematological or biochemical parameters or tissue levels were observed in the mice. Given these findings, this compound demonstrates significant cytotoxic effects and has the potential to serve as a promising chemotherapeutic agent, warranting further investigation at more advanced stages.Numerous chemotherapeutic agents are currently employed in cancer treatment, but many are associated with significant side effects. This study aims to identify a novel anticancer drug that minimizes or eliminates these adverse effects. The anticancer activity of the Rhodium (III) complex cis-[RhLI2]I was evaluated through both in vivo and in vitro functional assays. Apoptosis in cancer cells post-treatment was assessed using microscopy and gene expression analysis. In cytotoxicity screening via the brine shrimp lethality bioassay, the compound exhibited an LC50 value of 25.90 µg/mL (P < 0.001). It also achieved an 88.96% inhibition of cell growth (P < 0.001), an 82.39% increase in lifespan (P < 0.001), and a significant reduction in tumor weight at a dosage of 200 µg/kg in Ehrlich ascites carcinoma (EAC)-bearing Swiss albino mice. Restoration of hematological parameters, such as RBC, WBC, and hemoglobin levels, was observed in treated tumor-bearing mice compared to untreated EAC-bearing mice. The compound inhibited the growth and proliferation of breast cancer (MCF7) cells in a dose-dependent manner, achieving a maximum inhibition of 88.9% at 200 µg/mL. Apoptotic induction in MCF7 cells occurred through the upregulation of p53, Bax, caspase-3, -8, and -9, alongside the downregulation of the anti-apoptotic protein Bcl-2. No long-term adverse effects on hematological or biochemical parameters or tissue levels were observed in the mice. Given these findings, this compound demonstrates significant cytotoxic effects and has the potential to serve as a promising chemotherapeutic agent, warranting further investigation at more advanced stages.]]></description><identifier>ISSN: 2730-6011</identifier><identifier>EISSN: 2730-6011</identifier><identifier>DOI: 10.1007/s12672-024-01632-7</identifier><language>eng</language><ispartof>Discover. Oncology, 2024-12, Vol.15 (1), p.782</ispartof><rights>2024. The Author(s).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,862,27907,27908</link.rule.ids></links><search><creatorcontrib>Hossain, M Matakabbir</creatorcontrib><creatorcontrib>Soha, Kazi</creatorcontrib><creatorcontrib>Rahman, Arifur</creatorcontrib><creatorcontrib>Auwal, Abdul</creatorcontrib><creatorcontrib>Pronoy, Tasfik Ul Haque</creatorcontrib><creatorcontrib>Rashel, K M</creatorcontrib><creatorcontrib>Nurujjaman, M</creatorcontrib><creatorcontrib>Rahman, Habibur</creatorcontrib><creatorcontrib>Roy, Tapashi G</creatorcontrib><creatorcontrib>Khanam, Jahan Ara</creatorcontrib><creatorcontrib>Islam, Farhadul</creatorcontrib><title>Rhodium complex RhLI2I: a novel anticancer agent inducing tumor inhibition and apoptosis</title><title>Discover. Oncology</title><description><![CDATA[Numerous chemotherapeutic agents are currently employed in cancer treatment, but many are associated with significant side effects. This study aims to identify a novel anticancer drug that minimizes or eliminates these adverse effects. The anticancer activity of the Rhodium (III) complex cis-[RhLI2]I was evaluated through both in vivo and in vitro functional assays. Apoptosis in cancer cells post-treatment was assessed using microscopy and gene expression analysis. In cytotoxicity screening via the brine shrimp lethality bioassay, the compound exhibited an LC50 value of 25.90 µg/mL (P < 0.001). It also achieved an 88.96% inhibition of cell growth (P < 0.001), an 82.39% increase in lifespan (P < 0.001), and a significant reduction in tumor weight at a dosage of 200 µg/kg in Ehrlich ascites carcinoma (EAC)-bearing Swiss albino mice. Restoration of hematological parameters, such as RBC, WBC, and hemoglobin levels, was observed in treated tumor-bearing mice compared to untreated EAC-bearing mice. The compound inhibited the growth and proliferation of breast cancer (MCF7) cells in a dose-dependent manner, achieving a maximum inhibition of 88.9% at 200 µg/mL. Apoptotic induction in MCF7 cells occurred through the upregulation of p53, Bax, caspase-3, -8, and -9, alongside the downregulation of the anti-apoptotic protein Bcl-2. No long-term adverse effects on hematological or biochemical parameters or tissue levels were observed in the mice. Given these findings, this compound demonstrates significant cytotoxic effects and has the potential to serve as a promising chemotherapeutic agent, warranting further investigation at more advanced stages.Numerous chemotherapeutic agents are currently employed in cancer treatment, but many are associated with significant side effects. This study aims to identify a novel anticancer drug that minimizes or eliminates these adverse effects. The anticancer activity of the Rhodium (III) complex cis-[RhLI2]I was evaluated through both in vivo and in vitro functional assays. Apoptosis in cancer cells post-treatment was assessed using microscopy and gene expression analysis. In cytotoxicity screening via the brine shrimp lethality bioassay, the compound exhibited an LC50 value of 25.90 µg/mL (P < 0.001). It also achieved an 88.96% inhibition of cell growth (P < 0.001), an 82.39% increase in lifespan (P < 0.001), and a significant reduction in tumor weight at a dosage of 200 µg/kg in Ehrlich ascites carcinoma (EAC)-bearing Swiss albino mice. Restoration of hematological parameters, such as RBC, WBC, and hemoglobin levels, was observed in treated tumor-bearing mice compared to untreated EAC-bearing mice. The compound inhibited the growth and proliferation of breast cancer (MCF7) cells in a dose-dependent manner, achieving a maximum inhibition of 88.9% at 200 µg/mL. Apoptotic induction in MCF7 cells occurred through the upregulation of p53, Bax, caspase-3, -8, and -9, alongside the downregulation of the anti-apoptotic protein Bcl-2. No long-term adverse effects on hematological or biochemical parameters or tissue levels were observed in the mice. Given these findings, this compound demonstrates significant cytotoxic effects and has the potential to serve as a promising chemotherapeutic agent, warranting further investigation at more advanced stages.]]></description><issn>2730-6011</issn><issn>2730-6011</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqVirFKBDEUAIMoeOj9gNUrbaIvyW6CtqJ4YHVcYXfEbLyNZPPWfYn4-V5hYWs1MzBCXCm8UYjulpW2TkvUnURljZbuRKy0MygtKnX6x8_FmvkDEXWvjMF-JV63Iw2pTRBomnP8hu34stGbe_BQ6Ctm8KWm4EuIC_hDLBVSGVpI5QC1TbQcc0xvqSYqx3UAP9NciRNfirN3nzmuf3khrp8edw_Pcl7os0Wu-ylxiDn7Eqnx3qjO3vXGds78Y_0BBSBNIA</recordid><startdate>20241218</startdate><enddate>20241218</enddate><creator>Hossain, M Matakabbir</creator><creator>Soha, Kazi</creator><creator>Rahman, Arifur</creator><creator>Auwal, Abdul</creator><creator>Pronoy, Tasfik Ul Haque</creator><creator>Rashel, K M</creator><creator>Nurujjaman, M</creator><creator>Rahman, Habibur</creator><creator>Roy, Tapashi G</creator><creator>Khanam, Jahan Ara</creator><creator>Islam, Farhadul</creator><scope>7X8</scope></search><sort><creationdate>20241218</creationdate><title>Rhodium complex RhLI2I: a novel anticancer agent inducing tumor inhibition and apoptosis</title><author>Hossain, M Matakabbir ; Soha, Kazi ; Rahman, Arifur ; Auwal, Abdul ; Pronoy, Tasfik Ul Haque ; Rashel, K M ; Nurujjaman, M ; Rahman, Habibur ; Roy, Tapashi G ; Khanam, Jahan Ara ; Islam, Farhadul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_31469536473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hossain, M Matakabbir</creatorcontrib><creatorcontrib>Soha, Kazi</creatorcontrib><creatorcontrib>Rahman, Arifur</creatorcontrib><creatorcontrib>Auwal, Abdul</creatorcontrib><creatorcontrib>Pronoy, Tasfik Ul Haque</creatorcontrib><creatorcontrib>Rashel, K M</creatorcontrib><creatorcontrib>Nurujjaman, M</creatorcontrib><creatorcontrib>Rahman, Habibur</creatorcontrib><creatorcontrib>Roy, Tapashi G</creatorcontrib><creatorcontrib>Khanam, Jahan Ara</creatorcontrib><creatorcontrib>Islam, Farhadul</creatorcontrib><collection>MEDLINE - Academic</collection><jtitle>Discover. Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hossain, M Matakabbir</au><au>Soha, Kazi</au><au>Rahman, Arifur</au><au>Auwal, Abdul</au><au>Pronoy, Tasfik Ul Haque</au><au>Rashel, K M</au><au>Nurujjaman, M</au><au>Rahman, Habibur</au><au>Roy, Tapashi G</au><au>Khanam, Jahan Ara</au><au>Islam, Farhadul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rhodium complex RhLI2I: a novel anticancer agent inducing tumor inhibition and apoptosis</atitle><jtitle>Discover. Oncology</jtitle><date>2024-12-18</date><risdate>2024</risdate><volume>15</volume><issue>1</issue><spage>782</spage><pages>782-</pages><issn>2730-6011</issn><eissn>2730-6011</eissn><abstract><![CDATA[Numerous chemotherapeutic agents are currently employed in cancer treatment, but many are associated with significant side effects. This study aims to identify a novel anticancer drug that minimizes or eliminates these adverse effects. The anticancer activity of the Rhodium (III) complex cis-[RhLI2]I was evaluated through both in vivo and in vitro functional assays. Apoptosis in cancer cells post-treatment was assessed using microscopy and gene expression analysis. In cytotoxicity screening via the brine shrimp lethality bioassay, the compound exhibited an LC50 value of 25.90 µg/mL (P < 0.001). It also achieved an 88.96% inhibition of cell growth (P < 0.001), an 82.39% increase in lifespan (P < 0.001), and a significant reduction in tumor weight at a dosage of 200 µg/kg in Ehrlich ascites carcinoma (EAC)-bearing Swiss albino mice. Restoration of hematological parameters, such as RBC, WBC, and hemoglobin levels, was observed in treated tumor-bearing mice compared to untreated EAC-bearing mice. The compound inhibited the growth and proliferation of breast cancer (MCF7) cells in a dose-dependent manner, achieving a maximum inhibition of 88.9% at 200 µg/mL. Apoptotic induction in MCF7 cells occurred through the upregulation of p53, Bax, caspase-3, -8, and -9, alongside the downregulation of the anti-apoptotic protein Bcl-2. No long-term adverse effects on hematological or biochemical parameters or tissue levels were observed in the mice. Given these findings, this compound demonstrates significant cytotoxic effects and has the potential to serve as a promising chemotherapeutic agent, warranting further investigation at more advanced stages.Numerous chemotherapeutic agents are currently employed in cancer treatment, but many are associated with significant side effects. This study aims to identify a novel anticancer drug that minimizes or eliminates these adverse effects. The anticancer activity of the Rhodium (III) complex cis-[RhLI2]I was evaluated through both in vivo and in vitro functional assays. Apoptosis in cancer cells post-treatment was assessed using microscopy and gene expression analysis. In cytotoxicity screening via the brine shrimp lethality bioassay, the compound exhibited an LC50 value of 25.90 µg/mL (P < 0.001). It also achieved an 88.96% inhibition of cell growth (P < 0.001), an 82.39% increase in lifespan (P < 0.001), and a significant reduction in tumor weight at a dosage of 200 µg/kg in Ehrlich ascites carcinoma (EAC)-bearing Swiss albino mice. Restoration of hematological parameters, such as RBC, WBC, and hemoglobin levels, was observed in treated tumor-bearing mice compared to untreated EAC-bearing mice. The compound inhibited the growth and proliferation of breast cancer (MCF7) cells in a dose-dependent manner, achieving a maximum inhibition of 88.9% at 200 µg/mL. Apoptotic induction in MCF7 cells occurred through the upregulation of p53, Bax, caspase-3, -8, and -9, alongside the downregulation of the anti-apoptotic protein Bcl-2. No long-term adverse effects on hematological or biochemical parameters or tissue levels were observed in the mice. Given these findings, this compound demonstrates significant cytotoxic effects and has the potential to serve as a promising chemotherapeutic agent, warranting further investigation at more advanced stages.]]></abstract><doi>10.1007/s12672-024-01632-7</doi></addata></record>
fulltext fulltext
identifier ISSN: 2730-6011
ispartof Discover. Oncology, 2024-12, Vol.15 (1), p.782
issn 2730-6011
2730-6011
language eng
recordid cdi_proquest_miscellaneous_3146953647
source DOAJ Directory of Open Access Journals; PubMed Central Open Access; Springer Nature - Complete Springer Journals; PubMed Central
title Rhodium complex RhLI2I: a novel anticancer agent inducing tumor inhibition and apoptosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T08%3A50%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rhodium%20complex%20RhLI2I:%20a%20novel%20anticancer%20agent%20inducing%20tumor%20inhibition%20and%20apoptosis&rft.jtitle=Discover.%20Oncology&rft.au=Hossain,%20M%20Matakabbir&rft.date=2024-12-18&rft.volume=15&rft.issue=1&rft.spage=782&rft.pages=782-&rft.issn=2730-6011&rft.eissn=2730-6011&rft_id=info:doi/10.1007/s12672-024-01632-7&rft_dat=%3Cproquest%3E3146953647%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3146953647&rft_id=info:pmid/&rfr_iscdi=true